Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

214 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Drugs That Modify Cholesterol Metabolism Alter the p38/JNK-Mediated Targeted and Nontargeted Response to Alpha and Auger Radioimmunotherapy.
Ladjohounlou R, Lozza C, Pichard A, Constanzo J, Karam J, Le Fur P, Deshayes E, Boudousq V, Paillas S, Busson M, Le Blay M, Jarlier M, Marcatili S, Bardiès M, Bruchertseifer F, Morgenstern A, Torgue J, Navarro-Teulon I, Pouget JP. Ladjohounlou R, et al. Among authors: busson m. Clin Cancer Res. 2019 Aug 1;25(15):4775-4790. doi: 10.1158/1078-0432.CCR-18-3295. Epub 2019 May 6. Clin Cancer Res. 2019. PMID: 31061069 Free article.
Brief intraperitoneal radioimmunotherapy of small peritoneal carcinomatosis using high activities of noninternalizing 125I-labeled monoclonal antibodies.
Boudousq V, Ricaud S, Garambois V, Bascoul-Mollevi C, Boutaleb S, Busson M, Quenet F, Colombo PE, Bardiès M, Kotzki PO, Navarro-Teulon I, Pèlegrin A, Pouget JP. Boudousq V, et al. Among authors: busson m. J Nucl Med. 2010 Nov;51(11):1748-55. doi: 10.2967/jnumed.110.080226. Epub 2010 Oct 18. J Nucl Med. 2010. PMID: 20956481 Free PMC article.
Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb.
Boudousq V, Bobyk L, Busson M, Garambois V, Jarlier M, Charalambatou P, Pèlegrin A, Paillas S, Chouin N, Quenet F, Maquaire P, Torgue J, Navarro-Teulon I, Pouget JP. Boudousq V, et al. Among authors: busson m. PLoS One. 2013 Jul 29;8(7):e69613. doi: 10.1371/journal.pone.0069613. Print 2013. PLoS One. 2013. PMID: 23922757 Free PMC article.
Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis.
Leconet W, Chentouf M, du Manoir S, Chevalier C, Sirvent A, Aït-Arsa I, Busson M, Jarlier M, Radosevic-Robin N, Theillet C, Chalbos D, Pasquet JM, Pèlegrin A, Larbouret C, Robert B. Leconet W, et al. Among authors: busson m. Clin Cancer Res. 2017 Jun 1;23(11):2806-2816. doi: 10.1158/1078-0432.CCR-16-1316. Epub 2016 Dec 6. Clin Cancer Res. 2017. PMID: 27923843
Antibody targeting of claudin-1 as a potential colorectal cancer therapy.
Cherradi S, Ayrolles-Torro A, Vezzo-Vié N, Gueguinou N, Denis V, Combes E, Boissière F, Busson M, Canterel-Thouennon L, Mollevi C, Pugnière M, Bibeau F, Ychou M, Martineau P, Gongora C, Del Rio M. Cherradi S, et al. Among authors: busson m. J Exp Clin Cancer Res. 2017 Jun 28;36(1):89. doi: 10.1186/s13046-017-0558-5. J Exp Clin Cancer Res. 2017. PMID: 28659146 Free PMC article.
A recycling anti-transferrin receptor-1 monoclonal antibody as an efficient therapy for erythroleukemia through target up-regulation and antibody-dependent cytotoxic effector functions.
Neiveyans M, Melhem R, Arnoult C, Bourquard T, Jarlier M, Busson M, Laroche A, Cerutti M, Pugnière M, Ternant D, Gaborit N, Chardès T, Poupon A, Gouilleux-Gruart V, Pèlegrin A, Poul MA. Neiveyans M, et al. Among authors: busson m. MAbs. 2019 Apr;11(3):593-605. doi: 10.1080/19420862.2018.1564510. Epub 2019 Feb 18. MAbs. 2019. PMID: 30604643 Free PMC article.
214 results